Summit Securities Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $304K | Sell |
1,210
-3,280
| -73% | -$706K | 0.03% | 224 |
|
|
2026
Q1 | $977K | Buy |
4,490
+1,604
| +56% | +$356K | 0.12% | 95 |
|
|
2025
Q4 | $659K | Sell |
2,886
-5,158
| -64% | -$1.17M | 0.09% | 166 |
|
|
2025
Q3 | $1.86M | Buy |
8,044
+5,385
| +203% | +$1.1M | 0.38% | 61 |
|
|
2025
Q2 | $494K | Buy |
2,659
+2,059
| +343% | +$383K | 0.1% | 147 |
|
|
2025
Q1 | $126K | Buy |
600
+384
| +178% | +$74.7K | 0.02% | 214 |
|
|
2024
Q4 | $38.4K | Buy |
216
+16
| +8% | +$2.94K | 0.01% | 310 |
|
|
2024
Q3 | $39K | Sell |
200
-600
| -75% | -$112K | 0.01% | 254 |
|
|
2024
Q2 | $137K | Sell |
800
-40,200
| -98% | -$6.66M | 0.03% | 192 |
|
|
2024
Q1 | $7.47M | Buy |
41,000
+5,550
| +16% | +$957K | 1.23% | 15 |
|
|
2023
Q4 | $5.49M | Buy |
35,450
+4,950
| +16% | +$722K | 0.5% | 33 |
|
|
2023
Q3 | $4.55M | Sell |
30,500
-5,605
| -16% | -$823K | 0.47% | 34 |
|
|
2023
Q2 | $4.86M | Buy |
36,105
+736
| +2% | +$108K | 0.63% | 27 |
|
|
2023
Q1 | $5.64M | Sell |
35,369
-5,048
| -12% | -$772K | 0.46% | 42 |
|
|
2022
Q4 | $6.53M | Sell |
40,417
-13,064
| -24% | -$2M | 0.25% | 65 |
|
|
2022
Q3 | $7.18M | Buy |
53,481
+26,188
| +96% | +$3.76M | 0.54% | 38 |
|
|
2022
Q2 | $4.18M | Sell |
27,293
-7,034
| -20% | -$1.07M | 0.52% | 37 |
|
|
2022
Q1 | $5.57M | Sell |
34,327
-69,791
| -67% | -$10.1M | 0.62% | 31 |
|
|
2021
Q4 | $14.1M | Buy |
104,118
+73,618
| +241% | +$8.7M | 0.66% | 27 |
|
|
2021
Q3 | $3.29M | Sell |
30,500
-17,996
| -37% | -$2.06M | 0.26% | 93 |
|
|
2021
Q2 | $5.46M | Buy |
48,496
+25,745
| +113% | +$2.9M | 0.45% | 43 |
|
|
2021
Q1 | $2.46M | Sell |
22,751
-40,502
| -64% | -$4.33M | 0.27% | 77 |
|
|
2020
Q4 | $6.78M | Sell |
63,253
-1,192
| -2% | -$115K | 0.57% | 39 |
|
|
2020
Q3 | $5.64M | Buy |
64,445
+47,772
| +287% | +$4.5M | 0.59% | 33 |
|
|
2020
Q2 | $1.64M | Sell |
16,673
-4,111
| -20% | -$362K | 0.2% | 98 |
|
|
2020
Q1 | $1.58M | Sell |
20,784
-102,073
| -83% | -$8.69M | 0.28% | 80 |
|
|
2019
Q4 | $10.9M | Buy |
122,857
+109,157
| +797% | +$9.06M | 0.82% | 26 |
|
|
2019
Q3 | $1.04M | Buy |
13,700
+7,300
| +114% | +$500K | 0.09% | 131 |
|
|
2019
Q2 | $465K | Sell |
6,400
-4,900
| -43% | -$385K | 0.05% | 216 |
|
|
2019
Q1 | $911K | Sell |
11,300
-2,100
| -16% | -$172K | 0.17% | 84 |
|
|
2018
Q4 | $1.24M | Sell |
13,400
-1,600
| -11% | -$141K | 0.11% | 120 |
|
|
2018
Q3 | $1.42M | Buy |
15,000
+6,500
| +76% | +$616K | 0.53% | 38 |
|
|
2018
Q2 | $788K | Buy |
8,500
+6,200
| +270% | +$606K | 0.11% | 99 |
|
|
2018
Q1 | $218K | Sell |
2,300
-32,600
| -93% | -$3.58M | 0.05% | 130 |
|
|
2017
Q4 | $3.38M | Buy |
34,900
+27,900
| +399% | +$2.63M | 0.4% | 22 |
|
|
2017
Q3 | $622K | Buy |
+7,000
| New | +$533K | 0.11% | 93 |
|
|
2016
Q3 | – | Sell |
-5,948
| Closed | -$368K | – | 151 |
|
|
2016
Q2 | $368K | Buy |
5,948
+1,964
| +49% | +$120K | 0.2% | 123 |
|
|
2016
Q1 | $228K | Sell |
3,984
-8,964
| -69% | -$500K | 0.16% | 121 |
|
|
2015
Q4 | $767K | Buy |
12,948
+6,308
| +95% | +$363K | 0.25% | 65 |
|
|
2015
Q3 | $361K | Buy |
6,640
+5,931
| +837% | +$386K | 0.26% | 54 |
|
|
2015
Q2 | $48K | Sell |
709
-1,388
| -66% | -$90.6K | 0.02% | 212 |
|
|
2015
Q1 | $123K | Sell |
2,097
-4,328
| -67% | -$261K | 0.09% | 115 |
|
|
2014
Q4 | $420K | Buy |
6,425
+625
| +11% | +$39.4K | 0.12% | 122 |
|
|
2014
Q3 | $335K | Buy |
5,800
+3,100
| +115% | +$172K | 0.1% | 150 |
|
|
2014
Q2 | $152K | Buy |
2,700
+600
| +29% | +$31.5K | 0.05% | 190 |
|
|
2014
Q1 | $108K | Sell |
2,100
-23,700
| -92% | -$1.2M | 0.06% | 132 |
|
|
2013
Q4 | $1.36M | Buy |
25,800
+14,900
| +137% | +$732K | 0.24% | 58 |
|
|
2013
Q3 | $488K | Sell |
10,900
-5,400
| -33% | -$239K | 0.17% | 68 |
|
|
2013
Q2 | $674K | Buy |
+16,300
| New | +$713K | 0.32% | 55 |
|
Other funds holding ABBV
Summit Securities Group's ABBV Position: Q2 2026 in Review
Summit Securities Group reduced its AbbVie (ABBV) stake by 73% in Q2 2026, selling an estimated $706K and leaving 1,210 shares worth $304K. The position accounts for 0.03% of the portfolio, ranked #224.
Summit Securities Group first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $14.1M in Q4 2021. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Summit Securities Group held 1,210 shares of AbbVie worth $304K as of Q2 2026.
- Summit Securities Group sold 3,280 AbbVie shares in Q2 2026, an estimated $706K.
- AbbVie made up 0.03% of Summit Securities Group's portfolio in Q2 2026, its #224 holding.
- Summit Securities Group first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
- Summit Securities Group's AbbVie position peaked at $14.1M in Q4 2021.
- 4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.